BiOWiSH Technologies, Inc. | July 22, 2022
BiOWiSH Technologies, Inc. and SABIC Agri-Nutrients Company announced the successful completion of a year-long technical evaluation of BiOWiSH® Crop Liquid technology coated on SABIC’s urea in nine countries across five continents and nine different crop types.
BiOWiSH® Crop Liquid is a blend of proprietary microbial cultures that can be coated onto dry fertilizer or mixed with liquid fertilizers to create an enhanced efficiency fertilizer specifically designed to optimize yield potential and improve soil productivity.
Featuring the company’s proprietary HoloGene 3™ technology, BiOWiSH® Crop Liquid creates a high-performance partnership between the plant and BiOWiSH microorganisms. The new alliance has a combined genetic profilethat enhances native microbial activity in the soil, promotes soil quality, and supports the plant’s natural ability to resist environmental stress. This optimizes crop yield potential by increasing nutrient availability and improving soil productivity and plant vigor.
This unique mode of action, combined with the product’s industry-leading shelf life, is proven to achieve consistent desired results across a broad range of operating conditions, climates and environments – all at a low cost to farmers.
“We are thrilled to confirm that SABIC AN Bio-Enhanced Urea powered by BiOWiSH® has performed extremely well in the field,”
Munif Al-Munif, General Manager Agri-Nutrients Technology at SABIC AN
“Our uniform, high-crushing strength urea combined with the superior technology of BiOWiSH® Crop Liquid delivers extended stability and consistent performance at a price per acre farmers can afford. In an industry challenged with high regulatory pressures and global food demand, we are excited to offer a sustainable product that safely increases crop production and generates higher profits for growers,” he added.
The market launch of SABIC AN Enhanced Urea will initially be fulfilled through SABIC AN partners in select target countries while the teams work together to expand in other regions around the world. The launch follows extensive successful testing of the product across multiple international markets, including the United States.
The Bio-Enhanced Urea, powered by BiOWiSH®, will be available at the same price as standard urea through the Archer-Daniels-Midland Company (ADM) and American Plant Food (APF) for a limited time in select areas. Customers can contact their ADM or APF representative for more details.
In addition, SABIC AN and BiOWiSH have constructed a joint development platform designed to advance further customizations across a range of SABIC AN’s high-efficiency fertilizers. This partnership is the foundation for future products and other agronomic innovations.
“We appreciate the close collaboration with SABIC AN’s team,” said BiOWiSH CEO Ian Edwards. “It is very exciting that a market-leading fertilizer company such as SABIC AN recognizes the importance of biologicals and is placing such high focus and energy on bringing Bio-Enhanced Mineral Fertilizer to customers across the globe. Together, we will work toward our shared goal of developing agricultural solutions that help farmers maximize productivity and increase income – while at the same time, improving environmental outcomes.”
SABIC AN Bio-Enhanced Urea will be available to farmers in additional locations in the future, enabling growers to experience the benefits of BiOWiSH®-powered fertilizer.
About BiOWiSH Technologies
Headquartered in Cincinnati, Ohio, BiOWiSH Technologies, Inc. is a global provider of biotechnology solutions for the agriculture, aquaculture, and environmental management industries. As a leader in the agricultural market, we help farmers increase crop production sustainably, safely and cost effectively. Our revolutionary BiOWiSH® Crop Liquid can be coated onto dry fertilizer or mixed with liquid fertilizer to create an enhanced efficiency fertilizer that optimizes yield potential, expresses plant vigor and improves soil productivity across a broad range of operating conditions, climates and environments. By unifying nature and science, BiOWiSH reinvents the way food is grown.
About SABIC Agri-Nutrients Company
SABIC AN is a public joint stock company listed on the Saudi Stock Exchange where SABIC owns 50.1% with the remaining 49.9% being held by the private sector and the public. It is one of the leading global fertilizer producers. SABIC AN portfolio includes urea, ammonia, phosphate and other specialized products.
BeiGene | August 16, 2022
BeiGene a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today announced a strategic agreement with Ontada®, a McKesson business with leading provider technology and actionable real-world research, education, and evidence in oncology, to improve U.S. community oncology care through the development of real-world evidence data, tools, and insights to help increase access to affordable, cutting-edge therapies.
The partnership will be led by Ontada and focus on accelerating the development and implementation of RWE to improve community education on the financial impact and value of oncolytics as well as improve patient access to oncology medicines.
“BeiGene is excited to work with Ontada to advance our shared vision of improving patient access, affordability, and value for community oncology stakeholders and key partners working at the intersection of clinical practice and real-world evidence. Working together, BeiGene and Ontada will generate novel oncology insights through real-world data, tools, and technologies that will facilitate the acceleration of precise decision-making in support of community oncology practices whose ultimate mission is to improve patient outcomes.”
Josh Neiman, Chief Commercial Officer, North America and Europe, at BeiGene
As part of the collaboration, the companies will optimize the use of RWE to communicate value across key stakeholders including patients, providers, and payers; develop timely education on emerging science and therapeutic differentiation; and collaborate to advance use of RWE in healthcare and regulatory decision making to increase timely and affordable patient access to life-saving oncology therapies.
“BeiGene aims to bring 10 molecules per year to the clinic starting in 2023 and, as this research advances, we’re delighted to form this strategic partnership with McKesson, which shares the same vision as BeiGene for improving the care of cancer patients,” said Christiane Langer, M.D., Senior Vice President of Global Medical Affairs, Ex-China, at BeiGene. “This collaboration will leverage Ontada’s technology platform and deep understanding of the experiences of patients treated in community oncology clinics to help accelerate both the development of the BeiGene portfolio and expand access to treatment options.”
“As a leader in real-world research, Ontada is uniquely positioned to support complex research that uncovers deeper patient insights and perspectives that advance cancer care,” said Susan Shiff, Ph.D., president of Ontada. “We are excited to announce this unique partnership with BeiGene and look forward to developing a stronger understanding of how to better treat oncology patients through the use of real-world data and evidence.”
Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients’ lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and power the future of cancer care.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
BeiGene is committed to advancing best- and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines for patients across the globe. We have a growing R&D and medical affairs team of approximately 2,900 colleagues dedicated to advancing more than 100 clinical trials that have involved more than 16,000 subjects. Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions. Hematology-oncology and solid tumor targeted therapies and immuno-oncology are key focus areas for the Company, with both mono- and combination therapies prioritized in our research and development. BeiGene currently has three approved medicines discovered and developed in our own labs: BTK inhibitor BRUKINSA® in the U.S., China, the European Union, Great Britain, Canada, Australia, and additional international markets; and the non-Fc-gamma receptor binding anti-PD-1 antibody, tislelizumab, as well as the PARP inhibitor, pamiparib, in China.
BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs. We commercialize a range of oncology medicines in China licensed from Amgen, Bristol Myers Squibb, EUSA Pharma and Bio-Thera. We also plan to address greater areas of unmet need globally through our other collaborations including with Mirati Therapeutics, Seagen, and Zymeworks.
In January 2021, BeiGene and Novartis announced a collaboration granting Novartis rights to co-develop, manufacture, and commercialize BeiGene’s anti-PD1 antibody, tislelizumab, in North America, Europe, and Japan. Building upon this productive collaboration, BeiGene and Novartis announced an option, collaboration, and license agreement in December 2021 for BeiGene’s TIGIT inhibitor, ociperlimab, that is in Phase 3 development. Novartis and BeiGene also entered into a strategic commercial agreement through which BeiGene will promote five approved Novartis Oncology products across designated regions of China.
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 8,500 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland.
Fauna | June 15, 2022
Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the most serious human diseases. Orca is another new update to the Convergence platform, and enables direct comparison of gene expression signatures from naturally disease-resistant species with those from humans. Convergence now leverages genomic analyses across 452 mammal species (65 of which are hibernators), an 86 percent increase from two years ago.
Much of the company's focus is cardiac and pulmonary diseases, where current treatments mainly focus on symptom management rather than treating the underlying condition. Faun1003, a compound discovered through LEO (Fauna Bio's drug prediction module), is being investigated for use in lung injury and pulmonary hypertension. While uniquely differentiated, retrospective analyses of similar compounds show a survival advantage in critical care settings for patients with lung injury that receive this drug, providing additional human support for the target of Faun1003.
Fauna Bio's first neuronal program, Faun264G, looks to improve the survival of human neurons deprived of glucose. A pilot study found knockdown of 264G in-vivo impairs the ability of 13-lined ground squirrels to enter torpor, validating its function. Fauna will continue with expanded in-vivo experiments to understand its role in controlling metabolism this summer. Fauna Bio has also initiated a new discovery program in inflammatory bowel disease, seeking targets to improve epithelial barrier function and reduce immune cell migration. Forty-five percent of compounds predicted for use in IBD by LEO have already been investigated, suggesting strong enrichment for IBD targets. The company has also completed brain cortex and kidney sequencing, with target predictions coming soon.
These updates build on the company's momentum since raising $9M in funding last year. Since then, Fauna has expanded partnerships with leading academic institutions, including the University of Wisconsin-Oshkosh and Monash University in Australia. Both collaborations focus on studying genes from the 13-lined ground squirrel that allow for survival during hibernation under extreme conditions. Monash University will assist in additional pre-clinical testing of Fauna compounds, while UW-O supports the existing colony, additional tissue collections, and in-vivo experiments. Through a new partnership with the University of Nevada - Las Vegas, Fauna will add genes from tenrecs, a second hibernating species, to Fauna Bio's proprietary biobank.
We continue to see how the power of comparative genomics, and looking outside of our own species, is like building a stronger magnet to help us find that elusive needle in the haystack. By introducing a small amount of the right data and applying it in the right way, we can more quickly identify the real opportunities to make a difference for people suffering from diseases with unmet needs, We've had incredible support from the National Human Genomics Research Institute, the National Institute of Health, our investors, and advisors to continue educating and bringing these programs closer to finding real therapeutic solutions for many of the worst human diseases."
Ashley Zehnder, Ph.D., D.V.M, CEO of Fauna Bio.
About Fauna Bio
Fauna Bio is an end-to-end target and drug discovery platform company and a pioneer in computational, comparative and translational genomics. Fauna Bio is mining the shared genetics between mammals and humans to pinpoint specific genes and pathways that result in disease resistance to some of the most common and deadly human diseases. With a proprietary biobank that includes thousands of tissue samples across multiple species and time points, unparalleled data curation, comparative genomics, machine learning-based target predictions and compound predictions, the Fauna Bio platform identifies extraordinary genes which are highly conserved across species and predicts small molecules that replicate disease resistance to jumpstart human drug development.